Knight Andrew
Animal Consultants International, London, UK.
Altern Lab Anim. 2008 Dec;36(6):709-12. doi: 10.1177/026119290803600614.
Highly polarised viewpoints about animal experimentation have often prevented agreement. However, important common ground between advocates and opponents was demonstrated within a discussion forum hosted at www.research-methodology.org.uk in July-August 2008, by the independent charity, SABRE Research UK. Agreement existed that many animal studies have methodological flaws - such as inappropriate sample sizes, lack of randomised treatments, and unblinded outcome assessments - that may introduce bias and limit statistical validity. There was also agreement that systematic reviews of the human utility of animal models yield the highest quality of evidence, as their reliance on methodical and impartial methods to select significant numbers of animal studies for review, serves to minimise bias. Unfortunately, disagreement remained that animal experimental licence applications should reference systematic reviews of existing studies, before approval. The UK Medical Research Council requires that researchers planning human clinical trials must reference such reviews of related previous work. Existing knowledge is thereby fully and appropriately utilised, and redundant experimentation is avoided. However, objections were raised that a similar requirement would interfere with animal experimental licensing, because, to date, there have been very few systematic reviews of animal studies. In fact, the relative dearth of such reviews is a matter of considerable concern, and may partially explain the very poor human success rates of drugs that appear safe and/or efficacious in animal trials. Nevertheless, the disturbing number of human trials which have proceeded concurrently with, or prior to, animal studies, or have continued despite equivocal evidence of efficacy in animals, clearly demonstrate that many researchers fail to conduct adequate prior reviews of existing evidence. Where neither sufficient primary studies, nor systematic reviews of such studies, exist, for citation within a licence application, researchers should be able to provide evidence of this shortcoming, and, concurrently, demonstrate that the available literature and evidence have been adequately reviewed. This should also enable them to clearly demonstrate the need and scientific appropriateness of their proposed study, the validity of its design, and - importantly - that the benefits are reasonably likely to exceed the animal welfare, bioethical and financial costs. Invasive animal studies should never be permitted solely on the basis of less probable, speculative or intangible human benefits, or the mere satisfaction of scientific curiosity.
关于动物实验的极端两极化观点常常阻碍了达成共识。然而,2008年7月至8月期间,在英国独立慈善机构SABRE Research UK主办的、位于www.research - methodology.org.uk的一个讨论论坛上,动物实验的支持者和反对者之间展现出了重要的共同立场。大家一致认为,许多动物研究存在方法学缺陷,比如样本量不当、缺乏随机处理以及未设盲的结果评估等,这些可能会引入偏差并限制统计效度。此外,大家还一致认为,对动物模型的人类效用进行系统评价能产生最高质量的证据,因为其依靠系统且公正的方法来挑选大量动物研究进行评价,有助于将偏差降至最低。不幸的是,对于动物实验许可申请在获批前是否应参考现有研究的系统评价,仍存在分歧。英国医学研究理事会要求,计划开展人体临床试验的研究人员必须参考此类对相关先前工作的评价。这样就能充分且恰当地利用现有知识,并避免重复实验。然而,有人提出反对意见,认为类似要求会干扰动物实验许可,因为迄今为止,对动物研究的系统评价非常少。事实上,此类评价相对匮乏是一个相当令人担忧的问题,这或许能部分解释为何在动物试验中看似安全和/或有效的药物,应用于人体时成功率却极低。尽管如此,与动物研究同时进行、先于动物研究开展,或者在动物实验中疗效证据不明确的情况下仍继续进行的人体试验数量令人不安,这清楚地表明许多研究人员未能对现有证据进行充分的预先评价。如果在许可申请中既没有足够的原始研究,也没有对此类研究的系统评价可供引用,研究人员应该能够提供这一缺陷的证据,并同时证明已对现有文献和证据进行了充分审查。这也应使他们能够清楚地证明其拟开展研究的必要性和科学合理性、设计的有效性,以及——重要的是——其益处合理地有可能超过动物福利、生物伦理和财务成本。绝不应仅仅基于不太可能、推测性或无形的人类益处,或者仅仅为了满足科学好奇心就允许进行侵入性动物研究。